Evert Schimmelpennink

About Evert Schimmelpennink

Evert Schimmelpennink, 53, has served on Contineum Therapeutics’ Board since January 2022 and became independent Chair of the Board in March 2024 . He is President & CEO of LENZ Therapeutics (since March 2021) and previously was CEO of Pfenex (2017–2020, including acting PFO/PAO from November 2019 to sale), CEO of Alvotech (2015–2017), and held senior roles at Pfizer, Hospira and Synthon . He holds an M.Sc. in Bioprocess Engineering (Wageningen University, Netherlands) and a business degree from Arnhem Business School .

Past Roles

External Roles

Board Governance

• Independence: CTNM’s Board determined all directors except CEO Carmine Stengone and Diego Miralles are independent; Schimmelpennink is independent .
• Roles: Chair of the Board (separate from CEO), reinforcing independent oversight; non‑employee directors meet regularly in executive session without management .
• Committee assignments (as of 12/31/2024): Member, Compensation Committee; not on Audit or Nominating & Corporate Governance .
• Committee activity: Compensation Committee met 6 times in 2024; Audit met 4 times; Nominating & Corporate Governance met 2 times .
• Attendance: Board met 7 times in 2024; each director attended at least 75% of Board/committee meetings during their service period .

Committee Membership Snapshot (as of 12/31/2024)

Fixed Compensation

• 2024 Non‑Employee Director Compensation (actual): | Item | Amount | |---|---| | Fees earned (cash) | $56,628 | | Option awards (grant‑date fair value) | $426,346 | | Total | $482,974 | | Options outstanding at 12/31/2024 (count) | 61,590 |

• Standard Non‑Employee Director Cash Retainers (effective post‑IPO):
  | Role | Annual Retainer | |---|---| | Board Member | $40,000 | | Board Chair | $30,000 | | Audit Chair / Member | $15,000 / $7,500 | | Compensation Chair / Member | $10,000 / $5,000 | | Nominating & Governance Chair / Member | $8,000 / $4,000 |

• Equity Program (non‑employee directors): Initial option award equal to 0.090% of total shares outstanding at grant; annual option equal to 0.045% post‑AGM; time‑based vesting; full acceleration upon change in control .

Performance Compensation

• Non‑employee directors receive time‑based stock options; no performance‑conditioned metrics (e.g., revenue/EBITDA/TSR) are used in director pay design .

Other Directorships & Interlocks

• Current public company board: iBio, Inc. .
• Compensation Committee interlocks: Company discloses no interlocks or insider participation among executive officers in FY2024 .
• No related‑party transactions disclosed involving Schimmelpennink in FY2023–FY2024 RPT section .

Expertise & Qualifications

• Core strengths: CEO/operator across biotech (LENZ, Pfenex, Alvotech) with prior big‑pharma/specialty injectables experience (Pfizer/Hospira/Synthon) .
• Education: M.Sc. Bioprocess Engineering (Wageningen); business degree (Arnhem Business School) .
• Board leadership: Independent Board Chair since March 2024; separation of Chair/CEO highlighted in governance guidelines .

Equity Ownership

Governance Assessment

• Strengths:

  • Independent Chair with separation from CEO enhances oversight; regular executive sessions support independent deliberation .
  • Confirmed independence and active role on Compensation Committee (which engaged independent advisor Alpine in 2024); committee met 6 times, signaling engagement .
  • Director pay aligns with shareholder outcomes via equity options; change‑in‑control treatment is standard; no performance‑metric loopholes in director pay .
  • No related‑party transactions involving Schimmelpennink disclosed; Section 16 compliance affirmed broadly for insiders in 2024 .
  • Attendance at or above threshold across the Board; Board met 7 times in 2024 .

• Watch items / potential overextension risk:

  • Dual role as sitting CEO of LENZ plus CTNM Board Chair may increase time‑commitment load; continue monitoring attendance and responsiveness (Board reports ≥75% attendance; no individual shortfalls disclosed) .
  • Beneficial ownership currently reflects primarily option holdings; continue to monitor equity accumulation for alignment versus director ownership guidelines (no specific director ownership guidelines disclosed in the proxy) .

• Red flags:

  • None identified regarding conflicts, pledging/hedging, related‑party exposure, or compensation interlocks based on current disclosures .

Notes:

• Committee membership (as of 12/31/2024): Compensation Committee member (not chair) .
• Non‑employee director compensation details, retainers, and option structure per IPO‑adopted program; Evert’s 2024 cash and equity values are disclosed .
• Beneficial ownership based on 19,142,377 Class A shares outstanding at 3/14/2025; Evert’s holdings <1% .